• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ⅱ期鼻咽癌患者亚组的生存情况。

Survival among subgroups of patients with stage II nasopharyngeal carcinoma.

机构信息

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, People's Republic of China.

Department of Radiology, Guangxi Medical University Cancer Hospital, Qingxiu District, No. 71 Hedi Road, Nanning, 530021, Guangxi, People's Republic of China.

出版信息

Sci Rep. 2022 Apr 29;12(1):7007. doi: 10.1038/s41598-022-11145-4.

DOI:10.1038/s41598-022-11145-4
PMID:35488053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9054756/
Abstract

To assess survival between subgroups (T1N1, T2N0, and T2N1) of patients with stage II nasopharyngeal carcinoma (NPC). This retrospective cohort study evaluated pathologically confirmed stage II NPC patients from The Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2016. The included patients were divided into three subgroups: T1N1, T2N0, and T2N1. Overall survival (OS) and cancer-specific survival (CSS) were assessed using the Kaplan-Meier method among the three subgroups. This study investigated 836 patients: 383 (45.8%) patients were in the T1N1 subgroup, 175 (20.9%) patients were in the T2N0 subgroup, and 278 (33.3%) patients were in the T2N1 subgroup. The 5-year OS (75.7%, 68.6%, and 75.7%) and CSS (85.3%, 83.4%, and 84.5%) were similar among the T1N1, T2N0, and T2N1 subgroups. Univariate and multivariate regression analyses revealed that the subgroup (T1N1, T2N0, and T2N1) of stage II NPC was not an independent prognostic factor for OS or CSS. Survival was comparable among subgroups (T1N1, T2N0, and T2N1) of stage II NPC patients. However, patients with T1N1, T2N0, and T2N1 stage disease who receive different treatments might have different prognoses.

摘要

评估 II 期鼻咽癌（NPC）患者亚组（T1N1、T2N0 和 T2N1）之间的生存情况。本回顾性队列研究评估了 2004 年至 2016 年来自监测、流行病学和最终结果（SEER）数据库的经病理证实的 II 期 NPC 患者。将纳入的患者分为三组：T1N1、T2N0 和 T2N1。在这三组中，采用 Kaplan-Meier 法评估总生存率（OS）和癌症特异性生存率（CSS）。本研究共纳入 836 例患者：383 例（45.8%）患者为 T1N1 亚组，175 例（20.9%）患者为 T2N0 亚组，278 例（33.3%）患者为 T2N1 亚组。T1N1、T2N0 和 T2N1 亚组的 5 年 OS（75.7%、68.6%和 75.7%）和 CSS（85.3%、83.4%和 84.5%）相似。单因素和多因素回归分析表明，II 期 NPC 的亚组（T1N1、T2N0 和 T2N1）不是 OS 或 CSS 的独立预后因素。II 期 NPC 患者亚组（T1N1、T2N0 和 T2N1）之间的生存情况相当。然而，接受不同治疗的 T1N1、T2N0 和 T2N1 期疾病患者可能具有不同的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/55caf6509a1e/41598_2022_11145_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/491360339e6d/41598_2022_11145_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/a5cfee2cdf5b/41598_2022_11145_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/bfbaab8a523b/41598_2022_11145_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/6211da0be811/41598_2022_11145_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/4ceee5acc58f/41598_2022_11145_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/3455d85e4784/41598_2022_11145_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/b72c827afd60/41598_2022_11145_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/55caf6509a1e/41598_2022_11145_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/491360339e6d/41598_2022_11145_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/a5cfee2cdf5b/41598_2022_11145_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/bfbaab8a523b/41598_2022_11145_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/6211da0be811/41598_2022_11145_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/4ceee5acc58f/41598_2022_11145_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/3455d85e4784/41598_2022_11145_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/b72c827afd60/41598_2022_11145_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c931/9054756/55caf6509a1e/41598_2022_11145_Fig8_HTML.jpg

相似文献

1
Survival among subgroups of patients with stage II nasopharyngeal carcinoma.Ⅱ期鼻咽癌患者亚组的生存情况。
Sci Rep. 2022 Apr 29;12(1):7007. doi: 10.1038/s41598-022-11145-4.
2
Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.无同步放化疗的 II 期鼻咽癌患者与有同步放化疗的 II 期鼻咽癌患者的生存比较：一项倾向评分匹配研究。
Cancer Med. 2020 Feb;9(4):1287-1297. doi: 10.1002/cam4.2785. Epub 2019 Dec 20.
3
Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era.调强放射治疗时代II期鼻咽癌患者的长期生存情况
Jpn J Clin Oncol. 2016 Mar;46(3):241-7. doi: 10.1093/jjco/hyv192. Epub 2016 Jan 10.
4
Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.单纯调强放疗治疗早期鼻咽癌患者的长期疗效。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):327-33. doi: 10.1016/j.ijrobp.2010.09.011. Epub 2010 Oct 29.
5
Histological subtype remains a prognostic factor for survival in nasopharyngeal carcinoma patients.组织学亚型仍然是鼻咽癌患者生存的预后因素。
Laryngoscope. 2020 Mar;130(3):E83-E88. doi: 10.1002/lary.28099. Epub 2019 Jun 12.
6
Chemotherapy use and survival in stage II nasopharyngeal carcinoma.II期鼻咽癌的化疗应用与生存情况
Oncotarget. 2017 Oct 11;8(60):102573-102580. doi: 10.18632/oncotarget.21751. eCollection 2017 Nov 24.
7
Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China.在中国非流行地区，采用调强放射治疗联合或不联合化疗对主要为WHO II型组织学的早期鼻咽癌患者的临床结局。
Head Neck. 2014 Jun;36(6):841-7. doi: 10.1002/hed.23386. Epub 2013 Oct 4.
8
Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma.早期鼻咽癌患者单纯放疗后的治疗结果。
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1070-6. doi: 10.1016/j.ijrobp.2008.09.008. Epub 2009 Feb 21.
9
Efficacy of chemoradiotherapy in survival of stage Ⅳ nasopharyngeal carcinoma and establishment of a prognostic model.放化疗对Ⅳ期鼻咽癌生存的疗效及预后模型的建立。
Oral Oncol. 2022 Aug;131:105927. doi: 10.1016/j.oraloncology.2022.105927. Epub 2022 Jun 6.
10
Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis.基于人群分析：中危鼻咽癌患者同步放化疗与单纯放疗的长期疗效比较。
Eur Arch Otorhinolaryngol. 2023 Apr;280(4):1793-1802. doi: 10.1007/s00405-022-07726-8. Epub 2022 Nov 6.

引用本文的文献

1
Retrospective analysis of 1539 nasopharyngeal carcinoma cases: chemotherapy should not be excluded for non-Asian patients with T1-2N1M0 stage.对1539例鼻咽癌病例的回顾性分析：对于T1-2N1M0期的非亚洲患者，不应排除化疗。
Front Oncol. 2025 Jan 17;14:1529136. doi: 10.3389/fonc.2024.1529136. eCollection 2024.
2
An overall survival predictive nomogram to identify high-risk patients among locoregionally advanced nasopharyngeal carcinoma: Developed based on the SEER database and validated institutionally.一种用于识别局部晚期鼻咽癌高危患者的总生存预测列线图：基于监测、流行病学和最终结果（SEER）数据库开发并经机构验证。
Front Oncol. 2023 Mar 16;13:1083713. doi: 10.3389/fonc.2023.1083713. eCollection 2023.

本文引用的文献

1
The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma.化疗对II期鼻咽癌患者生存率的疗效。
Oral Oncol. 2020 Feb;101:104520. doi: 10.1016/j.oraloncology.2019.104520. Epub 2019 Dec 13.
2
Ten-Year Outcomes Of Intensity-Modulated Radiotherapy (IMRT) Combine With Chemotherapy Versus IMRT Alone For Stage II Nasopharyngeal Carcinoma In The Real-World Study (RWD).真实世界研究（RWD）中，调强放疗（IMRT）联合化疗与单纯IMRT治疗II期鼻咽癌的十年结局
Cancer Manag Res. 2019 Oct 10;11:8893-8903. doi: 10.2147/CMAR.S218842. eCollection 2019.
3
Development and external validation of a nomogram for predicting the overall survival of patients with stage II nasopharyngeal carcinoma after curative treatment.
预测II期鼻咽癌患者根治性治疗后总生存的列线图的开发与外部验证
Cancer Manag Res. 2019 May 10;11:4403-4412. doi: 10.2147/CMAR.S202151. eCollection 2019.
4
Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study.模式的失败和生存趋势在 3808 例患者与第二阶段鼻咽癌诊断从 1990 年到 2012 年:一个大规模的回顾性队列研究。
Cancer Res Treat. 2019 Oct;51(4):1449-1463. doi: 10.4143/crt.2018.688. Epub 2019 Mar 7.
5
The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database.化疗在 II 期鼻咽癌治疗中的作用：国家癌症数据库的回顾性分析。
Cancer Med. 2019 Apr;8(4):1500-1507. doi: 10.1002/cam4.2033. Epub 2019 Feb 21.
6
Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.同期放化疗对比单纯放疗治疗 II 期鼻咽癌的 III 期随机临床试验的 10 年生存和毒性结局。
Eur J Cancer. 2019 Mar;110:24-31. doi: 10.1016/j.ejca.2018.10.020. Epub 2019 Feb 7.
7
Chemotherapy use and survival in stage II nasopharyngeal carcinoma.II期鼻咽癌的化疗应用与生存情况
Oncotarget. 2017 Oct 11;8(60):102573-102580. doi: 10.18632/oncotarget.21751. eCollection 2017 Nov 24.
8
Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma.调强放疗与二维常规放疗治疗Ⅱ期鼻咽癌的疗效比较。
Oncotarget. 2017 Apr 27;8(44):78096-78104. doi: 10.18632/oncotarget.17481. eCollection 2017 Sep 29.
9
Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.肿瘤体积与 EBV-DNA 联合可改善调强放疗时代 II 期鼻咽癌的预后分层：一项大规模队列研究。
Cancer Res Treat. 2018 Jul;50(3):861-871. doi: 10.4143/crt.2017.237. Epub 2017 Sep 13.
10
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.循环预处理爱泼斯坦-巴尔病毒DNA作为非流行地区局部晚期鼻咽癌的预后因素
Oncotarget. 2017 Jul 18;8(29):47780-47789. doi: 10.18632/oncotarget.17822.